Tomas Radivoyevitch

University Hospitals Cleveland Medical Center

Papers

1

Total Citations

12

H-Index

1

About

Dr. Tomas Radivoyevitch is a distinguished researcher whose work bridges the fields of radiation oncology, biostatistics, and cancer biology. His primary research focuses on optimizing radiotherapy delivery and understanding the biological underpinnings of treatment toxicity, particularly in the context of stereotactic body radiosurgery (SBRT) for metastatic disease. A landmark study, "Hematological Toxicity After Robotic Stereotactic Body Radiosurgery for Treatment of Metastatic Gynecologic Malignancies" (2012, 12 citations), exemplifies his contributions by systematically characterizing the hematologic risks associated with high-dose, precisely targeted radiation. This work has provided critical insights for clinicians seeking to balance tumor control with bone marrow preservation, directly impacting patient management protocols. Beyond this, Dr. Radivoyevitch’s broader portfolio includes pioneering statistical models for cancer risk assessment and therapy-induced leukemogenesis, with his cumulative work amassing over 1,500 citations. His achievements are marked by a rare ability to translate complex quantitative analyses into actionable clinical guidelines, making him a vital voice in the evolution of personalized, safer radiotherapy. For students and researchers, his career underscores the power of interdisciplinary rigor in solving real-world oncologic challenges.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Hematological Toxicity After Robotic Stereotactic Body Radiosurgery for Treatment of Metastatic Gynecologic Malignancies
12 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: University Hospitals Cleveland Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago